DEAL OF THE YEAR (>£500M)

This award recognises the teams and organisations who have executed a truly transformational and high value creating deal for both the company and the wider industry. The deal could be a licensing agreement, co-development or a creative alliance or partnership that unlocks significant value.

Qualifying criteria

• Deal size must be equal to or greater than £500m
• The lead company must be a European Life Science company
• Open to private or public companies WITH pharma, commercial leaders or big tech
• Deal can be either a licensing deal, single asset acquisition or collaborative agreement involving a particular drug, project or group of drugs/projects
• A license, partnership or alliance between companies NOT M&A
• Deal / milestone to have completed in the period between 1 September 2019 and 1 September 2020

Judges will be paying particular attention to:

• Uniqueness or novelty of deal strategy / terms and structure
• Level of value creation / size of deal (upfront, milestone and total value)
• Strength of partner / partnership and deal teams
• Potential game / industry changing implications within next 12-months
• Post-deal performance